Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09ZDY
|
|||
| Drug Name |
CAR138 T Cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Immune System disease [ICD-11: 4A01-4B41] | Phase 1 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1] | ||
| Company |
UNC Lineberger Comprehensive Cancer Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Syndecan-1 (SDC1) | Target Info | CAR-T-Cell-Therapy | [1] |
| Pathway Interaction Database | Beta3 integrin cell surface interactions | |||
| Integrins in angiogenesis | ||||
| Proteoglycan syndecan-mediated signaling events | ||||
| Syndecan-1-mediated signaling events | ||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.